Irritable Bowel Syndrome News

Nov 25, 2009 - Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc.

Find out what a sputtering economy and an increasingly difficult to crack job market means to you.

ALISO VIEJO,A Calif. A division of Valeant Pharmaceuticals has launched an authorized generic of an irritable bowel syndrome treatment.

Valeant Pharmaceuticals said Monday it began selling a generic version of Librax, a treatment for irritable bowel syndrome drug.

Two more privately-held companies are looking to enter the market, Ironwood Pharmaceuticals and Fabrinet .

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome and the other to treat complicated skin and skin structure and respiratory infections.

Eating disorder patients display a high prevalence of gastrointestinal symptoms and functional gastrointestinal disorders such as irritable bowel syndrome.

Ironwood did not specify in yesterday's filing how much it plans to raise by selling stock.

Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc. , today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza 24 microgram gel capsules for the long-term treatment of patients with chronic idiopathic constipation .

Many of us don't really know the differences between the symptoms of the common cold and the flu.

PPD, Inc. has entered an agreement with Janssen Pharmaceutica to develop and commercialize two Phase II therapeutic compounds, one for diarrhea-predominant irritable bowel syndrome and one for complicated skin and skin structure and respiratory infections.

Clinical research organization PPD on Tuesday announced it has reached an agreement with Belgian drug company Janssen Pharmaceutica N.V. to develop two compounds in a deal that could be worth hundreds of millions of dollars for both companies if the products reach the market.

Hypnosis has a "very real" effect that can be picked up on brain scans, say Hull University researchers.

Lexicon Pharmaceuticals Inc. said Friday an irritable bowel syndrome drug candidate met its goals in a mid-stage clinical trial.

IBS is more common in women. Fotalia Irritable bowel syndrome, or IBS, is a very common disorder of the digestive tract.

Wall Street News Alert is issuing its "Daily Market Movers Report" for Friday morning.

GastroIntestinal / Gastroenterology Lexicon Pharmaceuticals, Inc. announced that the company's investigational new drug, LX1031, a tryptophan hydroxylase inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome .

Probiotics are often recommended for those with digestive and stomach problems but recent research indicates that they can do a lot more by way of health benefits.

The drug Accutane has been used for many years to treat severe acne. It's often seen as the last resort for those who have acne that causes pitting and scarring on the face and body.

Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand.